## CITATION REPORT List of articles citing

Reviews on Biological Activity, Clinical Trial and Synthesis Progress of Small Molecules for the Treatment of COVID-19

DOI: 10.1007/s41061-020-00318-2 Topics in Current Chemistry, 2021, 379, 4.

Source: https://exaly.com/paper-pdf/78237273/citation-report.pdf

Version: 2024-04-19

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
10	COVID-19 into Chemical Science Perspective: Chemical Preventive Measures and Drug Development. <i>ChemistrySelect</i> , <b>2021</b> , 6, 2010-2028	1.8	3
9	Metal-Promoted Heterocyclization: A Heterosynthetic Approach to Face a Pandemic Crisis. <i>Molecules</i> , <b>2021</b> , 26,	4.8	О
8	Main Chemotypes of SARS-CoV-2 Reproduction Inhibitors. <i>Russian Journal of Organic Chemistry</i> , <b>2021</b> , 57, 730-767	0.7	
7	An outlook on suicide enzyme inhibition and drug design. Journal of the Iranian Chemical Society, 1	2	1
6	An Update on Pharmacological Relevance and Chemical Synthesis of Natural Products and Derivatives with Anti SARS-CoV-2 Activity <i>ChemistrySelect</i> , <b>2021</b> , 6, 11502-11527	1.8	3
5	Non-nucleoside structured compounds with antiviral activity-past 10 years (2010-2020) <i>European Journal of Medicinal Chemistry</i> , <b>2022</b> , 231, 114136	6.8	1
4	COVID-19 and the promise of small molecule therapeutics: Are there lessons to be learnt?. <i>Pharmacological Research</i> , <b>2022</b> , 179, 106201	10.2	3
3	Potential COVID-19 therapeutic approaches targeting angiotensin-converting enzyme 2; An updated review <i>Reviews in Medical Virology</i> , <b>2021</b> , e2321	11.7	4
2	Artificial Neural Network-Based Study Predicts GS-441524 as a Potential Inhibitor of SARS-CoV-2 Activator Protein Furin: a Polypharmacology Approach <i>Applied Biochemistry and Biotechnology</i> , <b>2022</b> , 1	3.2	1
1	Inhalable dry powder mRNA vaccines based on extracellular vesicles. <i>Matter</i> , <b>2022</b> ,	12.7	2